ISAL 2019 | Targeted RNA-sequencing for the quantification of MRD in AML

Christopher Hourigan

Quantitative PCR and flow cytometry can be utilized for the quantification of measurable residual disease (MRD), both of which have their pros and cons. Here, Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses the use of targeted RNA sequencing for the quantification of MRD in acute myeloid leukemia (AML). This assay, which can be customized and expanded, is the first demonstrated use of high-sensitivity RNA sequencing for MRD detection in AML and could serve as a broadly applicable standardized tool. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
https://www.ncbi.nlm.nih.gov/pubmed/30171026

Share this video